Europe Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class ; Route of Administration ; Application ; and Distribution Channel, and Country

The Europe gastrointestinal drugs market is expected to reach US$ 17,810.81 million by 2027 from US$ 12,721.85 million in 2019; it is expected to grow at a CAGR of 4.4% from 2020 to 2027. Rising prevalence of gastrointestinal (GI) diseases and increase in development of biologics are expected to boost the growth of the market. However, factors such as low awareness associated with gastrointestinal disorders in low-income economies are likely to restrain the growth of the market. Additionally, increasing investment in research activities coupled with growing pipeline of GI candidates and emergence of biosimilars are likely to fuel the growth of the gastrointestinal drugs market during the forecast period.
Gastrointestinal disorders are medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum.The disorders include constipation, irritable bowel, ulcerative colitis (UC), and peptic ulcer diseases.

These disorders are characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting.These disorders constitute a large proportion of outpatients and frequent hospital visits.

A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and emergence of biosimilars are expected to drive the market during the forecast period.
Increasing development of biologics for the treatment of GI diseases is driving the market.In the last few years, new treatments called biologics were being used for the treatment of inflammatory diseases.

Currently, the FDA has approved Humira, Cimzia, Remicade, Simponi, Tysabri, and Entyvio biologics for the treatment of Crohn’s disease and ulcerative colitis.Biologics have revolutionized the inflammatory bowel disease (IBD), treatment, and their success in the treatment of these indications is driving the use of biologics in other GI conditions, such as celiac disease, eosinophilic esophagitis, and autoimmune hepatitis.

The development of new medication is driving the market.For instance, in September 2019, Janssen Pharmaceutical received the European Commission approval for STELARA.

It would be used in the treatment of moderately to severely active ulcerative colitis in adults. It is the first biologic treatment that would target the IL-12/IL-23 pathway, an important therapeutic target in UC. Apart from this, strategic initiatives by market players, such as product launch in untapped markets, are further driving the market. The introduction of new biologics is expected to fuel the market growth during the forecast period.
Along with product launches, the market players are carrying out different strategies to add innovative therapies in their product portfolio.This is further boosting the growth of the gastrointestinal drugs market.

Many people are living with celiac disease, and they manage their symptoms by following a gluten-free diet. There is still no treatment for people who experience severe symptoms.
The European economy is severely affected due to the exponential growth of COVID-19 cases in the region.Short-term impacts of COVID-19 pandemic include demand changes, revision in regulatory process, changes in research and development process and shift toward telecommunication and telemedicine.

However, growing awareness about gastrointestinal products available in market in Europe is likely to boost the demand for constipation drug products and supply in COVID-19 pandemic, hence, it can boost the growth of the gastrointestinal drugs market.
In 2019, the acid neutralizers segment accounted for the highest share of the market.However, the biologics segment is expected to be the fastest-growing segment during the forecast period.

The biologics segment is anticipated to register the highest CAGR during the forecast period. The growth of the segment is attributed to growing product development and increasing product launches in the market.
A few of the major secondary sources associated with the Europe gastrointestinal drugs market report are World Health Organization, European Federation of Crohn’s & Ulcerative Colitis Associations, Centers of Disease Control and Prevention, International Foundation for Gastrointestinal Disorders, and National Institute of Health.